Rationale and design of the HEALTHY-CATH trial: A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients by Broom, Jennifer K et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Nephrology
Open Access Study protocol
Rationale and design of the HEALTHY-CATH trial: A randomised 
controlled trial of Heparin versus EthAnol Lock THerapY for the 
prevention of Catheter Associated infecTion in Haemodialysis 
patients
Jennifer K Broom1, Stacey O'Shea2, Sridevi Govindarajulu2, E 
Geoffrey Playford3, Carmel M Hawley2, Nicole M Isbel2, Scott B Campbell2, 
David W Mudge2, Sally Carpenter2, Barbara C Johnson3, Neil P Underwood3 
and David W Johnson*2
Address: 1Department of Medicine, Nambour General Hospital, Nambour, Australia, 2Department of Nephrology, University of Queensland at 
Princess Alexandra Hospital, Brisbane, Australia and 3Infection Management Service, University of Queensland at Princess Alexandra Hospital, 
Brisbane, Australia
Email: Jennifer K Broom - jennifer_broom@health.qld.gov.au; Stacey O'Shea - stacey_oshea@health.qld.gov.au; 
Sridevi Govindarajulu - grsridevi_nephro@yahoo.com; E Geoffrey Playford - geoffrey_playford@health.qld.gov.au; 
Carmel M Hawley - carmel_hawley@health.qld.gov.au; Nicole M Isbel - nikky_isbel@health.qld.gov.au; 
Scott B Campbell - scottB_campbell@health.qld.gov.au; David W Mudge - david_mudge@health.qld.gov.au; 
Sally Carpenter - sally_carpenter@health.qld.gov.au; Barbara C Johnson - barbara_johnson@health.qld.gov.au; 
Neil P Underwood - neil_underwood@health.qld.gov.au; David W Johnson* - david_johnson@health.qld.gov.au
* Corresponding author    
Abstract
Background:  Catheter-related bacteraemias (CRBs) contribute significantly to morbidity,
mortality and health care costs in dialysis populations. Despite international guidelines
recommending avoidance of catheters for haemodialysis access, hospital admissions for CRBs have
doubled in the last decade. The primary aim of the study is to determine whether weekly instillation
of 70% ethanol prevents CRBs compared with standard heparin saline.
Methods/design: The study will follow a prospective, open-label, randomized controlled design.
Inclusion criteria are adult patients with incident or prevalent tunneled intravenous dialysis
catheters on three times weekly haemodialysis, with no current evidence of catheter infection and
no personal, cultural or religious objection to ethanol use, who are on adequate contraception and
are able to give informed consent. Patients will be randomized 1:1 to receive 3 mL of intravenous-
grade 70% ethanol into each lumen of the catheter once a week and standard heparin locks for
other dialysis days, or to receive heparin locks only. The primary outcome measure will be time to
the first episode of CRB, which will be defined using standard objective criteria. Secondary
outcomes will include adverse reactions, incidence of CRB caused by different pathogens, time to
infection-related catheter removal, time to exit site infections and costs. Prospective power
calculations indicate that the study will have 80% statistical power to detect a clinically significant
increase in median infection-free survival from 200 days to 400 days if 56 patients are recruited into
each arm.
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Discussion:  This investigator-initiated study has been designed to provide evidence to help
nephrologists reduce the incidence of CRBs in haemodialysis patients with tunnelled intravenous
catheters.
Trial Registration: Australian New Zealand Clinical Trials Registry Number:
ACTRN12609000493246
Background
Central venous catheterization is an increasingly common
method of providing rapid, temporary access for the pro-
vision of haemodialysis (HD) to patients with serious
acute or chronic kidney failure. Unfortunately, the clinical
usefulness of this method is severely limited by the fre-
quent occurrence of bloodstream infections in up to 40%
of cases [1-4]. A number of registry [5,6] and observa-
tional cohort studies [7] have indicated that there has
been an increasing reliance on haemodialysis catheters in
incident haemodialysis patients ranging from 30% of
patients in Europe and Australia to 60% in the United
States of America [8-14]. Hospital admissions for catheter-
related bacteraemias (CRBs) have doubled in the last dec-
ade [15] and a recent analysis of the Dialysis Morbidity
and Mortality Wave 2 study [16] identified initial dialysis
access as the main antecedent of bacteraemia in dialysis
patients. Recent studies have further suggested that the use
of haemodialysis catheters is associated with a 1.5- to 3-
fold increase in both all-cause and infectious mortality
[17-19].
Blood stream infections can result from extraluminal (exit
site or tunnel infections) or intraluminal infection of the
catheter [20]. Strategies for preventing CRBs have gener-
ally focused on cutaneous antisepsis, topical antibiotic
application, antibiotic lock solutions and the use of
devices coated or impregnated with antimicrobial agents
[21,22]. However, these prophylactic strategies have been
limited by concerns about antibiotic toxicity and the
appearance of antibiotic-resistant microbial isolates
[23,24]. Sodium citrate locks have also been investigated
for prophylaxis against CRBs [25], although increased
rates of catheter thrombosis have been reported [26].
Locking of catheters with ethanol is a promising tech-
nique in this respect as the agent is bactericidal, has low
toxicity, is unlikely to produce resistant organisms, is able
to disinfect organisms in biofilms, and is cheap. Ethanol
is an antiseptic agent which is bacteriocidal by protein
denaturation and is active against a wide variety of organ-
isms including Gram-positive bacteria, Gram-negative
bacteria, and fungi. In vitro studies have been published
demonstrating the bactericidal effect of 70% ethanol
against plastic-adherent organisms that commonly cause
line infections [27]. Complete eradication of Gram-nega-
tive bacilli, Gram-positive cocci, and Candida albicans bio-
films occurred with 30 minutes treatment with 60%
ethanol compared to no eradication with trisodium cit-
rate 46.7%.
The effects of catheter exposure to ethanol have been
assessed and published. Silicone dialysis catheter integrity
is maintained as assessed by scanning electron micros-
copy, even after 15 days exposure to 95% ethanol solu-
tions [28]. The amount of silicone released was not
significantly different when the catheter was submerged in
ethanol compared to 0.9% sodium chloride. Mechanical
testing of polyurethane and silicone catheters exposed to
ten weeks of 70% ethanol proved ongoing structural
integrity of both catheter types after prolonged ethanol
exposure [29].
Published data has also demonstrated the effectiveness of
ethanol lock therapy in the prevention of CRBs in haema-
tology inpatients [16]. A short daily lock in haematology
inpatients was used, which is not practical for long term
use in renal dialysis outpatients. The current study is
designed to ask whether a weekly lock could reduce the
rate of CRBs in haemodialysis outpatients.
Methods/design
Ethics approval for the trial has been obtained from the
Princess Alexandra Hospital Human Research Ethics
Committee prior to study initiation and patient enrol-
ment. The study will be performed in accordance with the
2000 Edinburgh, Scotland Revision of the Declaration of
Helsinki, the National Health and Medical Research Com-
mittee (NHMRC) Statement on Human Experimentation,
Joint NHMRC/AVCC Statement and Guidelines on
Research Practice, applicable ICH guidelines and the Ther-
apeutic Goods Administration (TGA) – Note for guidance
on good clinical practice (CPMP/ICH/135/95) annotated
with TGA.
Participants
Participants will be selected from patients undergoing
haemodialysis with incident and prevalent tunnelled
intravenous catheters (Fig. 1). Inclusion criteria will
include the presence of a tunnelled intravenous catheter
and the ability to give informed consent. Exclusion criteria
will include:
1. Pregnancy or breast-feedingBMC Nephrology 2009, 10:23 http://www.biomedcentral.com/1471-2369/10/23
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Schema for the Ethanol Lock Trial Figure 1
Schema for the Ethanol Lock Trial.BMC Nephrology 2009, 10:23 http://www.biomedcentral.com/1471-2369/10/23
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2. Religious or personal objection to the use of ethanol
3. Intolerance to ethanol
4. History of an exit site, tunnel or blood stream infec-
tion associated with the current catheter
Study Design
The study will follow a prospective, open-label, ran-
domised, controlled design. Adequate allocation conceal-
ment will be ensured using a centralised computer-
generated block randomisation procedure. Randomisa-
tion will occur on the day that trial consent is obtained
and will be conducted by calling a centralised number to
allocate the patient to a trial arm. Stratification will occur
for incident versus prevalent catheters.
Experimental Intervention
Patients in the experimental arm will receive weekly instil-
lation of 3 mL intravenous-grade 70% ethanol into each
lumen of the catheter. Ethanol (Dehydrated alcohol USP
injection, Phebra Pty Ltd, NSW 2066, Australia) is regis-
tered in Australia as an adjunct in the treatment of acute
methanol and ethylene glycol poisoning and is supplied
as a sterile solution of no less than 96.8% w/w of ethanol.
Ethanol is diluted to 70% with sterile Water for Injections
BP (Pfizer Australia Pty Ltd, NSW 2114 Australia) in a
syringe prior to insertion into the catheter lumen. Dual
lumen catheters receive 2 × 3 mL 70% ethanol, equivalent
to 0.42 standard alcohol units. The ethanol lock is
inserted immediately at the end of a haemodialysis ses-
sion and left in situ until the next dialysis session (48
hours). When the patient returns for a further dialysis ses-
sion, the ethanol lock will be aspirated out of each lumen
of the catheter. For the remainder of the week patients in
the experimental arm will receive standard heparin locks
(Heparin sodium 5000 U/mL, Hospira, Germany).
Control Intervention
Patients in the control arm will only receive the standard
heparin lock into each lumen.
Concurrent Treatments
Patients in each trial arm will undergo standard exit site
and other management, as per the haemodialysis unit
protocol. This will include thrice weekly exit site applica-
tion of Medihoney (Medihoney™ Antibacterial Wound
Gel, Medihoney Pty Ltd, Brisbane, Australia).
Blinding
Blinding of investigators and patients is not possible as
the distinctive odour of 70% ethanol is immediately rec-
ognisable and unable to be concealed. Outcome assess-
ment based on standardised and objective criteria will be
performed by persons blinded to treatment allocation.
Outcome Measures
The primary outcome measure will be time to the first epi-
sode of CRB. CRB will be defined using standard objective
criteria [30-32]: (a) probable catheter-related bacteraemia
requires the isolation of a recognised pathogen from at
least one set of blood cultures (or a potential skin contam-
inant from at least two sets of blood cultures) in the set-
ting of clinical manifestations of sepsis with no other
apparent source of sepsis other than the catheter; (b)
definitive catheter-related bacteraemia requires the crite-
ria of probable catheter-related bacteraemia and one of:
purulence at the exit site; clinical sepsis that responds to
antibiotic therapy upon catheter removal (after being
refractory prior to catheter removal); or isolation of the
same organism from the removed catheter tip.
Secondary outcomes will include:
a. Incidence of CRB caused by different pathogens
b. Time to exit site infection
c. Time to infection-related catheter removal
d. Time to catheter removal
e. Adverse reactions
f. Quality of life
g. Economic cost
Clinical Assessment of Outcome
Reasons for removal of catheters will be assessed by med-
ical staff. Blood cultures will only be taken as clinically
indicated. The results of blood cultures collected during
the study period will be recorded by research staff. Com-
plications associated with lock therapy will be assessed on
a weekly basis by nursing assessment. Patients will also be
assessed for quality of life using the EQ-5D questionnaire,
which will be administered by the study nurse on a
monthly basis. They will also complete this questionnaire
if admitted to hospital during their involvement in the
trial. Data will be collected on health care service utiliza-
tion external to the hospital (such as general practitioner
visits) to allow economic evaluation in addition to the
hospital-associated costs during the trial.
Monitoring for Adverse Events
The number and proportion of subjections who report
treatment-emergent adverse events will be summarised
for each group.
A trial Safety and Data Monitoring Committee has been
set up to allow external evaluation of catheter-relatedBMC Nephrology 2009, 10:23 http://www.biomedcentral.com/1471-2369/10/23
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problems at 6 months and annually after that period. This
will consist of Renal and Infectious Diseases Physicians
not otherwise involved in the study, who will assess the
significance of catheter-associated problems in the treat-
ment vs control group.
Sample Size Calculations
Prospective power calculations indicate that the study will
have adequate statistical power (80% probability) to
detect a clinically significant increase in infection-free sur-
vival from 200 days to 400 days if 56 patients are recruited
into each arm (total 112 patients). These assumptions are
based on local data in haemodialysis patients at the Prin-
cess Alexandra Hospital. A recruitment period of 3 years is
anticipated.
Statistical Analyses
Infection-free survival curves, survival probabilities and
estimated survival times will be generated using Kaplan-
Meier methodology. Data will be censored at the time of
study completion and removal of catheter for non-infec-
tive reasons. The first occurrence of a relevant infective
event will be considered an event. Differences in the sur-
vival curves will be assessed using the log rank test. All
data will be analysed on an intention-to-treat basis. P val-
ues < 0.05 will be considered significant.
Discussion
This trial has been designed to assess the efficacy of etha-
nol locks in the prevention of catheter-associated bactere-
mia in haemodialysis patients. Anecdotal and case series
publications point to the potential efficacy of ethanol as a
lock therapy in prevention and treatment of central
venous catheter infection [33-35]. If effective, it will pro-
vide a cost-effective intervention which could substan-
tially reduce patient morbidity and mortality, in addition
to health-care associated costs. This trial will also prospec-
tively assess adverse events that may be associated with
ethanol use. In particular, the incidence of catheter-asso-
ciated thrombosis has proven problematic in recent trials
of sodium citrate locks [26]. There is a need for investiga-
tor-initiated trials of interventions such as this which do
not attract pharmaceutical company funding or interest,
but may provide important solutions to a clinical prob-
lems that confer substantial negative patient outcomes.
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